Phase 1 results point to larger trial of enzalutamide and fulvestrant in breast cancer
Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients ...
Dec 7, 2015
0
0